The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.34 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.86 — no flag raisedOK
- Earnings quality 90/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as AbbVie Inc. reports it. History and quarterly detail are in the app.
- Immunology$30.4B
- Neuroscience$10.8B
- Oncology$6.7B
- Aesthetics$4.9B
- Other Key Products$3.7B
Leadership changes
From AbbVie Inc.'s own filings, the day they're filed.
- Glenn F. Tilton · directors · departureeff. 2025-07-01
- David R. Purdue · President · appointmenteff. 2025-03-01
- Robert A. Michael · Chief Operating Officer · appointmenteff. 2023-06-29
Latest filings
- 8-K · Company announcement2026-07-06
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-04-29
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about AbbVie Inc., every answer cited🔒
- The Intelligence Brief — added when AbbVie Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.